Compare Kohl's Corporation (KSS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Moderna, Inc. — how do they compare? Kohl's Corporation trades at $20.35 (market cap $2.28B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 34.5× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Moderna, Inc. for 59 Days on average.
| KSS | MRNA | |
|---|---|---|
Market Cap | $2.28B | $78.65B |
Volume | 4,960,280 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $225.00 |
52-Week Low | $11.72 | $22.36 |
Typical Hold Time | 48 Days | 59 Days |
Enterprise Value | $7.88B | $74.80B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.10, down 0.1% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and a new merchandising appointment signal operational improvements. Revenue trends show stabilization after several quarters of decline, with 2026 projections indicating potential margin recovery.
KSS presents a value opportunity with deep discount to sector peers, though persistent sales declines and competitive pressures remain headwinds. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism amid turnaround execution risks.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
